Table of Contents
Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Competition Milieu
1.3. Segment Outlook
Chapter 2. Research Methodology
2.1. Information Procurement
2.2. Information or Data Analysis
2.3. Market Formulation & Validation
Chapter 3. Antibody Fragments Market Variables, Trends & Scope
3.1. Parent Market Analysis
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increasing prevalence of infectious and chronic diseases
3.2.1.2. Antibody fragments are preferred over other alternatives
3.2.1.3. Increasing public-private investments for pharma and biotech research
3.2.2. Market restraint analysis
3.2.2.1. Obstacles in the purification of antibody fragments
Chapter 4. Antibody Fragments Market: Segment Analysis, By Specificity, 2018 – 2030 (USD Million)
4.1. Definitions & Scope
4.2. Global Antibody Fragments Market, By Specificity, 2018 to 2030 (USD Million)
4.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 USD Million
4.3.1. Monoclonal Antibodies
4.3.1.1. Global Antibody Fragments Market, Monoclonal Antibodies, 2018 to 2030 (USD Million)
4.3.2. Polyclonal Antibodies
4.3.2.1. Global Antibody Fragments Market, Monoclonal Antibodies, 2018 to 2030 (USD Million)
Chapter 5. Antibody Fragments Market: Segment Analysis, By Type, 2018 – 2030 (USD Million)
5.1. Definitions & Scope
5.2. Global Antibody Fragments Market, By Type, 2018 to 2030 (USD Million)
5.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030
5.3.1. FAB
5.3.1.1. Global Antibody Fragments Market, FAB, 2018 to 2030 (USD Million)
5.3.2. scFv
5.3.2.1. Global Antibody Fragments Market,scFv, 2018 to 2030 (USD Million)
5.3.3. sdAb
5.3.3.1. Global Antibody Fragments Market, sdAb, 2018 to 2030 (USD Million)
5.3.4. Others
5.3.4.1. Global Antibody Fragments Market, others, 2018 to 2030 (USD Million)
Chapter 6. Antibody Fragments Market: Segment Analysis, By Therapy, 2018 – 2030 (USD Million)
6.1. Definitions & Scope
6.2. Global Antibody Fragments Market, By Therapy, 2018 to 2030 (USD Million)
6.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)
6.3.1. Monoclonal Antibodies
6.3.2. Praxbind (idarucizumab)
6.3.2.1. Global Antibody Fragments Market, Praxbind (idarucizumab), 2018 to 2030 (USD Million)
6.3.3. Ranibizumab (Lucentis)
6.3.3.1. Global Antibody Fragments Market, Ranibizumab (Lucentis), 2018 to 2030 (USD Million)
6.3.4. Certolizumab pegol (Cimzia)
6.3.4.1. Global Antibody Fragments Market, Certolizumab pegol (Cimzia), 2018 to 2030 (USD Million)
6.3.5. Iodine (1311) Metuximab/ Licartin
6.3.5.1. Global Antibody Fragments Market, Iodine (1311) Metuximab/ Licartin, 2018 to 2030 (USD Million)
6.3.6. Beovu (brolucizumab-dbll)
6.3.6.1. Global Antibody Fragments Market, Beovu (brolucizumab-dbll), 2018 to 2030 (USD Million)
6.3.7. Cablivi (caplacizumab-yhdp)
6.3.7.1. Global Antibody Fragments Market, Cablivi (caplacizumab-yhdp), 2018 to 2030 (USD Million)
6.3.8. Blinatumomab/ Blincyto
6.3.8.1. Global Antibody Fragments Market, Blinatumomab/ Blincyto, 2018 to 2030 (USD Million)
6.3.9. PAB
6.3.10. CroFab
6.3.10.1. Global Antibody Fragments Market, CroFab, 2018 to 2030 (USD Million)
6.3.11. Anavip
6.3.11.1. Global Antibody Fragments Market, Anavip, 2018 to 2030 (USD Million)
6.3.12. Anascorp
6.3.12.1. Global Antibody Fragments Market, Anascorp, 2018 to 2030 (USD Million)
6.3.13. Botulism Antitoxin Heptavalent (HBAT)
6.3.13.1. Global Antibody Fragments Market, Botulism Antitoxin Heptavalent (HBAT), 2018 to 2030 (USD Million)
6.3.14. Digibind
6.3.14.1. Global Antibody Fragments Market, Digibind, 2018 to 2030 (USD Million)
6.3.15. DigiFab
6.3.15.1. Global Antibody Fragments Market, DigiFab, 2018 to 2030 (USD Million)
6.3.16. Pipeline
6.3.17. AFM13
6.3.17.1. Global Antibody Fragments Market, AFM13, 2018 to 2030 (USD Million)
6.3.18. HPN-424
6.3.18.1. Global Antibody Fragments Market, HPN-424, 2018 to 2030 (USD Million)
6.3.19. MGD007
6.3.19.1. Global Antibody Fragments Market, MGD007, 2018 to 2030 (USD Million)
6.3.20. Tebotelimab (MGD013)
6.3.20.1. Global Antibody Fragments Market, Tebotelimab (MGD013), 2018 to 2030 (USD Million)
6.3.21. Bentracimab (PB2452)
6.3.21.1. Global Antibody Fragments Market, Bentracimab (PB2452), 2018 to 2030 (USD Million)
6.3.22. Flotetuzumab (MGD006)
6.3.22.1. Global Antibody Fragments Market, Flotetuzumab (MGD006), 2018 to 2030 (USD Million)
6.3.23. AK104
6.3.23.1. Global Antibody Fragments Market, AK104, 2018 to 2030 (USD Million)
6.3.24. Ozoralizumab
6.3.24.1. Global Antibody Fragments Market, Ozoralizumab, 2018 to 2030 (USD Million)
6.3.25. Sonelokimab (ALX0761)
6.3.25.1. Global Antibody Fragments Market, Sonelokimab (ALX0761), 2018 to 2030 (USD Million)
Chapter 7. Antibody Fragments Market: Segment Analysis, By Application, 2018 – 2030 (USD Million)
7.1. Definitions & Scope
7.2. Global Antibody Fragments Market, By Application, 2018 to 2030 (USD Million)
7.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 (USD Million)
7.3.1. Cancer
7.3.1.1. Global Antibody Fragments Market, Cancer, 2018 to 2030 (USD Million)
7.3.2. Immunodeficiency
7.3.2.1. Global Antibody Fragments Market, Immunodeficiency, 2018 to 2030 (USD Million)
7.3.3. Others
7.3.3.1. Global Antibody Fragments Market, Others, 2018 to 2030 (USD Million)
Chapter 8. Antibody Fragments Market: Regional Market Analysis, By Region, 2018 – 2030 (USD Million)
8.1. Definitions & Scope
8.2. Regional market share analysis, 2021&2030
8.3. Regional Market Dashboard
8.4. Regional Market: Key Players
8.5. Market Size, & Forecasts, and Trend Analysis, 2018 to 2030
8.6. North America
8.6.1. Market estimates and forecast, by Specificity, 2018 – 2030 (USD Million)
8.6.2. Market estimates and forecast, By Type, 2018 – 2030 (USD Million)
8.6.3. Market estimates and forecast, by Therapy, 2018 – 2030 (USD Million)
8.6.4. Market estimates and forecast, by Application, 2018 – 2030 (USD Million)
8.6.5. U.S.
8.6.5.1. Market estimates and forecast, by Specificity, 2018 – 2030 (USD Million)
8.6.5.2. Market estimates and forecast, By Type, 2018 – 2030 (USD Million)
8.6.5.3. Market estimates and forecast, by Therapy, 2018 – 2030 (USD Million)
8.6.5.4. Market estimates and forecast, by Application, 2018 – 2030 (USD Million)
8.6.6. Canada
8.6.6.1. Market estimates and forecast, by Specificity, 2018 – 2030 (USD Million)
8.6.6.2. Market estimates and forecast, By Type, 2018 – 2030 (USD Million)
8.6.6.3. Market estimates and forecast, by Therapy, 2018 – 2030 (USD Million)
8.6.6.4. Market estimates and forecast, by Application, 2018 – 2030 (USD Million)
8.7. Europe
8.7.1. Market estimates and forecast, by Specificity, 2018 – 2030 (USD Million)
8.7.2. Market estimates and forecast, By Type, 2018 – 2030 (USD Million)
8.7.3. Market estimates and forecast, by Therapy, 2018 – 2030 (USD Million)
8.7.4. Market estimates and forecast, by Application, 2018 – 2030 (USD Million)
8.7.5. Germany
8.7.5.1. Market estimates and forecast, by Specificity, 2018 – 2030 (USD Million)
8.7.5.2. Market estimates and forecast, By Type, 2018 – 2030 (USD Million)
8.7.5.3. Market estimates and forecast, by Therapy, 2018 – 2030 (USD Million)
8.7.5.4. Market estimates and forecast, by Application, 2018 – 2030 (USD Million)
8.7.6. U.K.
8.7.6.1. Market estimates and forecast, by Specificity, 2018 – 2030 (USD Million)
8.7.6.2. Market estimates and forecast, By Type, 2018 – 2030 (USD Million)
8.7.6.3. Market estimates and forecast, by Therapy, 2018 – 2030 (USD Million)
8.7.6.4. Market estimates and forecast, by Application, 2018 – 2030 (USD Million)
8.7.7. France
8.7.7.1. Market estimates and forecast, by Specificity, 2018 – 2030 (USD Million)
8.7.7.2. Market estimates and forecast, By Type, 2018 – 2030 (USD Million)
8.7.7.3. Market estimates and forecast, by Therapy, 2018 – 2030 (USD Million)
8.7.7.4. Market estimates and forecast, by Application, 2018 – 2030 (USD Million)
8.7.8. Italy
8.7.8.1. Market estimates and forecast, by Specificity, 2018 – 2030 (USD Million)
8.7.8.2. Market estimates and forecast, By Type, 2018 – 2030 (USD Million)
8.7.8.3. Market estimates and forecast, by Therapy, 2018 – 2030 (USD Million)
8.7.8.4. Market estimates and forecast, by Application, 2018 – 2030 (USD Million)
8.7.9. Spain
8.7.9.1. Market estimates and forecast, by Specificity, 2018 – 2030 (USD Million)
8.7.9.2. Market estimates and forecast, By Type, 2018 – 2030 (USD Million)
8.7.9.3. Market estimates and forecast, by Therapy, 2018 – 2030 (USD Million)
8.7.9.4. Market estimates and forecast, by Application, 2018 – 2030 (USD Million)
8.7.10. Russia
8.7.10.1. Market estimates and forecast, by Specificity, 2018 – 2030 (USD Million)
8.7.10.2. Market estimates and forecast, By Type, 2018 – 2030 (USD Million)
8.7.10.3. Market estimates and forecast, by Therapy, 2018 – 2030 (USD Million)
8.7.10.4. Market estimates and forecast, by Application, 2018 – 2030 (USD Million)
8.8. Asia Pacific
8.8.1. Market estimates and forecast, by Specificity, 2018 – 2030 (USD Million)
8.8.2. Market estimates and forecast, By Type, 2018 – 2030 (USD Million)
8.8.3. Market estimates and forecast, by Therapy, 2018 – 2030 (USD Million)
8.8.4. Market estimates and forecast, by Application, 2018 – 2030 (USD Million)
8.8.5. China
8.8.5.1. Market estimates and forecast, by Specificity, 2018 – 2030 (USD Million)
8.8.5.2. Market estimates and forecast, By Type, 2018 – 2030 (USD Million)
8.8.5.3. Market estimates and forecast, by Therapy, 2018 – 2030 (USD Million)
8.8.5.4. Market estimates and forecast, by Application, 2018 – 2030 (USD Million)
8.8.6. Japan
8.8.6.1. Market estimates and forecast, by Specificity, 2018 – 2030 (USD Million)
8.8.6.2. Market estimates and forecast, By Type, 2018 – 2030 (USD Million)
8.8.6.3. Market estimates and forecast, by Therapy, 2018 – 2030 (USD Million)
8.8.6.4. Market estimates and forecast, by Application, 2018 – 2030 (USD Million)
8.8.7. India
8.8.7.1. Market estimates and forecast, by Specificity, 2018 – 2030 (USD Million)
8.8.7.2. Market estimates and forecast, By Type, 2018 – 2030 (USD Million)
8.8.7.3. Market estimates and forecast, by Therapy, 2018 – 2030 (USD Million)
8.8.7.4. Market estimates and forecast, by Application, 2018 – 2030 (USD Million)
8.8.8. Australia
8.8.8.1. Market estimates and forecast, by Specificity, 2018 – 2030 (USD Million)
8.8.8.2. Market estimates and forecast, By Type, 2018 – 2030 (USD Million)
8.8.8.3. Market estimates and forecast, by Therapy, 2018 – 2030 (USD Million)
8.8.8.4. Market estimates and forecast, by Application, 2018 – 2030 (USD Million)
8.8.9. South Korea
8.8.9.1. Market estimates and forecast, by Specificity, 2018 – 2030 (USD Million)
8.8.9.2. Market estimates and forecast, By Type, 2018 – 2030 (USD Million)
8.8.9.3. Market estimates and forecast, by Therapy, 2018 – 2030 (USD Million)
8.8.9.4. Market estimates and forecast, by Application, 2018 – 2030 (USD Million)
8.8.10. Singapore
8.8.10.1. Market estimates and forecast, by Specificity, 2018 – 2030 (USD Million)
8.8.10.2. Market estimates and forecast, By Type, 2018 – 2030 (USD Million)
8.8.10.3. Market estimates and forecast, by Therapy, 2018 – 2030 (USD Million)
8.8.10.4. Market estimates and forecast, by Application, 2018 – 2030 (USD Million)
8.9. Latin America
8.9.1. Market estimates and forecast, by Specificity, 2018 – 2030 (USD Million)
8.9.2. Market estimates and forecast, By Type, 2018 – 2030 (USD Million)
8.9.3. Market estimates and forecast, by Therapy, 2018 – 2030 (USD Million)
8.9.4. Market estimates and forecast, by Application, 2018 – 2030 (USD Million)
8.9.5. Mexico
8.9.5.1. Market estimates and forecast, by Specificity, 2018 – 2030 (USD Million)
8.9.5.2. Market estimates and forecast, By Type, 2018 – 2030 (USD Million)
8.9.5.3. Market estimates and forecast, by Therapy, 2018 – 2030 (USD Million)
8.9.5.4. Market estimates and forecast, by Application, 2018 – 2030 (USD Million)
8.9.6. Brazil
8.9.6.1. Market estimates and forecast, by Specificity, 2018 – 2030 (USD Million)
8.9.6.2. Market estimates and forecast, By Type, 2018 – 2030 (USD Million)
8.9.6.3. Market estimates and forecast, by Therapy, 2018 – 2030 (USD Million)
8.9.6.4. Market estimates and forecast, by Application, 2018 – 2030 (USD Million)
8.9.7. Argentina
8.9.7.1. Market estimates and forecast, by Specificity, 2018 – 2030 (USD Million)
8.9.7.2. Market estimates and forecast, By Type, 2018 – 2030 (USD Million)
8.9.7.3. Market estimates and forecast, by Therapy, 2018 – 2030 (USD Million)
8.9.7.4. Market estimates and forecast, by Application, 2018 – 2030 (USD Million)
8.10. Middle East & Africa
8.10.1. Market estimates and forecast, by Specificity, 2018 – 2030 (USD Million)
8.10.2. Market estimates and forecast, By Type, 2018 – 2030 (USD Million)
8.10.3. Market estimates and forecast, by Therapy, 2018 – 2030 (USD Million)
8.10.4. Market estimates and forecast, by Application, 2018 – 2030 (USD Million)
8.10.5. South Africa
8.10.5.1. Market estimates and forecast, by Specificity, 2018 – 2030 (USD Million)
8.10.5.2. Market estimates and forecast, By Type, 2018 – 2030 (USD Million)
8.10.5.3. Market estimates and forecast, by Therapy, 2018 – 2030 (USD Million)
8.10.5.4. Market estimates and forecast, by Application, 2018 – 2030 (USD Million)
8.10.6. Saudi Arabia
8.10.6.1. Market estimates and forecast, by Specificity, 2018 – 2030 (USD Million)
8.10.6.2. Market estimates and forecast, By Type, 2018 – 2030 (USD Million)
8.10.6.3. Market estimates and forecast, by Therapy, 2018 – 2030 (USD Million)
8.10.6.4. Market estimates and forecast, by Application, 2018 – 2030 (USD Million)
8.10.7. UAE
8.10.7.1. Market estimates and forecast, by Specificity, 2018 – 2030 (USD Million)
8.10.7.2. Market estimates and forecast, By Type, 2018 – 2030 (USD Million)
8.10.7.3. Market estimates and forecast, by Therapy, 2018 – 2030 (USD Million)
8.10.7.4. Market estimates and forecast, by Application, 2018 – 2030 (USD Million)
Chapter 9. Competitive Landscape
9.1. Strategy Framework
9.2. Market Participation Categorization
9.3. Company Profile
9.3.1. Pfizer Inc
9.3.1.1. Company Overview
9.3.1.2. Financial Performance
9.3.1.3. Product Benchmarking
9.3.1.4. Strategic Initiatives
9.3.2. Sanofi
9.3.2.1. Company Overview
9.3.2.1.1. Albynx
9.3.2.1.1.1. Company Overview
9.3.2.2. Financial Performance
9.3.2.3. Product Benchmarking
9.3.2.4. Strategic Initiatives
9.3.3. Novartis AG
9.3.3.1. Company Overview
9.3.3.2. Financial Performance
9.3.3.3. Product Benchmarking
9.3.3.4. Strategic Initiatives
9.3.4. Genentech, Inc.
9.3.4.1. Company Overview
9.3.4.2. Financial Performance
9.3.4.3. Product Benchmarking
9.3.4.4. Strategic Initiatives
9.3.5. AbbVie Inc.
9.3.5.1. Company Overview
9.3.5.2. Financial Performance
9.3.5.3. Product Benchmarking
9.3.5.4. Strategic Initiatives
9.3.6. Bristol-Myers Squibb Company
9.3.6.1. Company Overview
9.3.6.2. Financial Performance
9.3.6.3. Product Benchmarking
9.3.6.4. Strategic Initiatives
9.3.7. Johnson & Johnson Services, Inc.
9.3.7.1. Company Overview
9.3.7.2. Financial Performance
9.3.7.3. Product Benchmarking
9.3.7.4. Strategic Initiatives
9.3.8. Lilly
9.3.8.1. Company Overview
9.3.8.2. Financial Performance
9.3.8.3. Product Benchmarking
9.3.8.4. Strategic Initiatives